A placebo controlled study to evaluate the safety and tolerability of repeat doses of SB-681323 in patients receiving methotrexate for rheumatoid arthritis.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs Dilmapimod (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 13 Jan 2012 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 13 Jan 2012 Actual patient number is 18 according to ClinicalTrials.gov.